Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
Edgewise Therapeutics Inc (NASDAQ: EWTX) closed the day trading at $14.0 down -1.06% from the previous closing price of $14.15. In other words, the price has decreased by -$1.06 from its previous closing price. On the day, 0.5 million shares were traded. EWTX stock price reached its highest trading level at $14.49 during the session, while it also had its lowest trading level at $13.91.
Ratios:
For a better understanding of EWTX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 28.87 and its Current Ratio is at 28.87. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Raymond James on July 30, 2025, initiated with a Strong Buy rating and assigned the stock a target price of $46.
On June 30, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $42.
On April 30, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $41.Guggenheim initiated its Buy rating on April 30, 2025, with a $41 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 12 ’25 when MOORE JOHN R sold 2,098 shares for $13.39 per share. The transaction valued at 28,097 led to the insider holds 10,214 shares of the business.
Derakhshan Behrad sold 2,491 shares of EWTX for $33,360 on Aug 12 ’25. The Chief Business Officer now owns 23,645 shares after completing the transaction at $13.39 per share. On Aug 12 ’25, another insider, Carruthers R Michael, who serves as the Chief Financial Officer of the company, sold 1,428 shares for $13.39 each. As a result, the insider received 19,124 and left with 86,162 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EWTX now has a Market Capitalization of 1474844032 and an Enterprise Value of 885113536.
Stock Price History:
The Beta on a monthly basis for EWTX is 0.26, which has changed by -0.29006088 over the last 52 weeks, in comparison to a change of 0.15222645 over the same period for the S&P500. Over the past 52 weeks, EWTX has reached a high of $38.12, while it has fallen to a 52-week low of $10.60. The 50-Day Moving Average of the stock is 0.40%, while the 200-Day Moving Average is calculated to be -35.39%.
Shares Statistics:
Over the past 3-months, EWTX traded about 799.18K shares per day on average, while over the past 10 days, EWTX traded about 630990 shares per day. A total of 105.34M shares are outstanding, with a floating share count of 74.59M. Insiders hold about 29.19% of the company’s shares, while institutions hold 84.75% stake in the company. Shares short for EWTX as of 1753920000 were 10192737 with a Short Ratio of 12.75, compared to 1751241600 on 12657398. Therefore, it implies a Short% of Shares Outstanding of 10192737 and a Short% of Float of 11.359999.
Earnings Estimates
The dynamic stock of Edgewise Therapeutics Inc (EWTX) is currently being evaluated by a team of 12.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.36 and low estimates of -$0.46.
Analysts are recommending an EPS of between -$1.56 and -$1.67 for the fiscal current year, implying an average EPS of -$1.62. EPS for the following year is -$1.94, with 11.0 analysts recommending between -$1.44 and -$2.35.
